Not currently recruiting at UCSF
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Hope Rugo, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Hope Rugo, MD
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Greenwich LifeSciences, Inc.
- ID
- NCT05232916
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 598 study participants
- Last Updated